TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Vaccine hesitancy score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of antiemetics combination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Strength (Handgrip Test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Absolute Oral Bioavailability (F) of CORT118335
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mass Balance Recovery in Excreta After a Single Oral Dose of 14C-CORT118335
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mass Balance Recovery in Urine After a Single Oral Dose of 14C-CORT118335
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mass Balance Recovery in Feces After a Single Oral Dose of 14C-CORT118335
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Organ toxicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy yield rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily variations of presepsin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in severity of most bothersome symptom (MBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in LVEF (left ventricular ejection fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of persons with or at high-risk of COPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptoms of chronic venous insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in number of hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Severe Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Medications knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mean Score of Anxiety Before Epidural Placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Score of Anxiety After Epidural Placement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: steady-state intramuscular levels of glycogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: steady-state intramuscular levels of Pi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: steady-state intramuscular levels of PCr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: steady-state intramuscular pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: kinetic rate constant of metabolic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ERP amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amyloid burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in plasma concentrations of NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in plasma concentrations of CK-MB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in plasma concentrations of cTnI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in State Rumination
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eradication rate (intention-to-treat analysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rate (per-protocol analysis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of IMU-201
Endpoint domain: Adverse events/effects
Primary endpoint: Analgesic effect of Tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Evaluated for Toxicity and Safety
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a T-cell Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cancer detection risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in usage of physician staffed EMS units
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Post-traumatic stress disorder scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Montreal Cognitive Assessment (MoCA) total score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of surgical repair of ventral hernias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: TNM primary colorectal tumor stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of OCT in diagnosing pancreatic cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: recurrence of ovarian masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sum Pain Intensity Difference Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Pain Relief Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: functional outcome one year after symptom onset
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Death or re-hospitalization for Worsening Heart Failure
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis of Acute Coronary Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Major Acute Cardiac Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: event-related potential (ERP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: power in specific frequency bands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eligibility to donor lung harvest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical resolution of trachoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: C. trachomatis infection clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient Pain Score With Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to achieve neutrophils > 500
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Granulocyte and platelet engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in minutes spent in moderate and vigorous intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rating of Aggression Against People and/or Property Scale (RAAPP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overt Aggression Scale-Modified (OAS-M)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Children's Aggression Scale-Parent Version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence to home-based rehabilitation program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: maximum amplitude of cerebral movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: average amplitude of cerebral movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 25 Hydroxy Vitamin D Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Wrinkle Length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global coronal implant position deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global apical implant position deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal coronal implant position deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal apical implant position deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angular implant position deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in resting metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach the maximum observed plasma concentration of JNJ-38877618
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to 24-hours post dose of JNJ-38877618
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in peroneal motor nerve conduction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall Protein Binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sentinel Lymph node detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Change from baseline VAS Sacroiliac Joint (SIJ) pain by at least 20 millimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of neurological worsening related to the lumbosacral nerve roots
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Tear Film Break-up Time (TFBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blink Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Have at Least One Treatment-Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Signs Measurements at Least Once Post-dose
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With at Least One Occurrence of Severe Hypoglycemia Post-dose
Endpoint domain: Adverse events/effects
Primary endpoint: Difference of Carotid artery IMT (mean IMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of participants with any treatment-emergent adverse event during the treatment period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with any abnormal, clinically significant clinical laboratory test value during the treatment period
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with any abnormal, clinically significant clinical electrocardiogram value during the treatment period
Endpoint domain: Adverse events/effects
Primary endpoint: Change in diabetes risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Activity Score (DAS28, 28-joint count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's visual analogue scale (VAS) for pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of the Vaginal Smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Infant intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain of the KOOS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of bronchopulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of mammography screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of screening by Pap smear or HPV test
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: ADCS-ADLsev
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete Clearance of AK Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with no live lice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Sartorius score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Carotid Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent Change in Cardiac Output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood Pressure before and after PLR test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate before and after PLR test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Hospital Falls
Endpoint domain: Adverse events/effects
Primary endpoint: plasma drug concentration of propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability assessed with EDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Generalized Anxiety Disorder 7 (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Social Phobia Inventory (SPIN)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Subjective Units of Distress Scale (SUDS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Retinal endothelial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vascular signaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Microparticle counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammation and immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of preparation in colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tracer accumulation exceeding normal uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to removal of all rigid immobilization for fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Venous Oxygen Saturation Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with Dose-Limiting Toxicities (DLTs) during the first treatment cycle
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) determination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with DLT-like events during the whole treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Positive and Negative Syndrome Scale (PANSS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Heart Failure Knowledge Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 24-Hour Smoking Abstinence (Week 26 Post Quit Day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in forearm muscle kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of conversions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in VAS score to assess pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of consent to inclusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from Baseline in Pain severity at 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Fatigue severity at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change from Baseline in Sleep quality at 4 weeks
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Wound Surface Area (WSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in back beliefs questionnaire for health care providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: total activity (step count)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Walking behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Inhibition of receptor and downstream signal transduction pathway activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration-time curve from time 0 to 48 hours (AUC0→48h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum drug concentration in plasma (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of the CTL response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of pain management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tidal electrical Impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood-to-brain clearance/trapping (K*) of [11C]AMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: distribution volume (DV) of [11C]harmine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Unplanned visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: breast cancer proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in number of medications taken daily
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of Participants Showing Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of HBeAg Positive Participants With HBV-DNA < 100,000 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With HBV-DNA < 20,000 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life (FACT-L Total Score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total postoperative opioid (morphine) consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in Diarrhea related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Alleviation of anginal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence or absence of bare spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification and location of bare spots
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average 24 hour glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Hemoglobin Increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression/regression of 3D plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean growth velocity in lower leg growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of using the MED-Go app
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Successful Identification of Vulvar Sentinel Lymph Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Patients Recovered With a Decrease in Global Contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients Recovered With Signs of Pericardial Effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients Recovered With Signs of Gadolinium Enhancement of Myocardium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-discharge mortality
Endpoint domain: Mortality/survival
Primary endpoint: Failure of patient perceived symptom control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Late high-grade AVB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes